Zinger Key Points
- Public comment period for the DEA's cannabis rescheduling proposal ending July 22 has sparked over 33,000 diverse opinions.
- Experts like Harvard's Dr. Peter Grinspoon, an advocate for full legalization, highlights cannabis’s therapeutic benefits.
- Benzinga's analysis of 4,000+ comments shows 75.9% support for cannabis rescheduling.
- Markets are swinging wildly, but for Matt Maley, it's just another opportunity to trade. His clear, simple trade alerts have helped members lock in gains as high as 100% and 450%. Now, you can get his next trade signal—completely free.
As the public comment period for the Drug Enforcement Administration’s (DEA) proposal to reclassify marijuana as a Schedule III substance under the Controlled Substances Act nears its July 22 deadline, the initiative has garnered significant public engagement. More than 33,000 comments have been submitted, reflecting a broad spectrum of opinions about cannabis policy in the U.S.
The proposal, initially published by the Department of Justice on May 21, suggests moving cannabis from Schedule I, which includes drugs deemed to have no medical use and a high potential for abuse, to Schedule III, which includes drugs with a lesser potential for abuse and accepted medical uses. This shift comes after the Department of Health and Human Services recommended the reclassification, acknowledging cannabis’s medical viability and lower abuse potential compared to substances like heroin and cocaine.
Broad Public Support For Rescheduling
Public sentiment, as aggregated by Benzinga from over 4,000 comments, shows wide support for rescheduling, with approximately 75.9% of feedback favoring the change. Many supporters emphasize the therapeutic benefits of cannabis and critique the outdated federal policies that do not align with current scientific understanding or state-level legalizations. However, a vocal minority insists on complete descheduling of cannabis, arguing that Schedule III status still imposes unnecessary federal restrictions.
Read Also: [Infographic] DEA’s Proposed Rules For Marijuana: What You Need To Know
Clashing Views On DEA Rescheduling Proposal
Dr. Peter Grinspoon, a cannabis specialist at Harvard Medical School, emphasized in his public comment, “Cannabis should be descheduled not rescheduled…it is markedly less harmful than tobacco or alcohol…and has vast therapeutic use,” noted Cannabis Business Times. This sentiment is echoed by the U.S. Cannabis Council’s executive director Edward Conklin, who in his comments praised the DEA’s action as “historic,” potentially leading to broader public health benefits and more robust cannabis research.
On the other end, opposition voices, represented in a comment by Smart Approaches to Marijuana argues that rescheduling could boost the cannabis industry similarly to big tobacco, potentially increasing cannabis use and associated harms, especially among youth.
Students Urged To Comment On Rescheduling
Anna Meyer, a legislative intern for Drug Policy Alliance, highlighted in a recent Filter Mag article that many college students, especially those from marginalized backgrounds, are unaware of the remaining opportunity to submit public comments on cannabis rescheduling. Meyer emphasized that federal prohibition continues to impose severe legal and educational consequences on students, such as loss of financial aid and future job prospects. Leveraging this comment period could push for descheduling, which she argues is necessary to fully eliminate these harms.
Deadline Nears For Public Comments Submission
As the deadline for public commentary approaches, the volume and content of responses underscore the importance Americans place on cannabis. For those interested in participating in this pivotal decision, comments can be submitted electronically through the Federal Register portal or by mail to the DEA until the evening of July 22.
Read Also:
Image generated with AI tools.
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!